Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03689543 · ClinicalTrials.gov registry record · Phase 2

Estrogen Receptor Beta and Mood

A Phase 2 study, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
Phase 2
Development phase
74
Enrollment target

NCT03689543: Completed Phase 2 study, sponsored by National Institute of Mental Health (NIMH).

NCT03689543 is a Phase 2 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 74 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03689543, a Phase 2 study, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
Phase 2
Development phase
74 participants
Enrollment target

Study Summary

Background: Our previous studies have found that women who had depression during the perimenopause may have mood symptoms again if they stop estrogen therapy. Estrogen acts in the brain and other tissues by binding to estrogen receptors. There are two main types of estrogen receptors. They are estrogen receptor alpha and beta. Several studies have shown that estrogen receptor beta may play an important role in anxiety- and depressive-like behaviors in animals. Objectives: To examine a possible mechanism mediating the effects of estradiol-withdrawal on mood symptoms in asymptomatic postmenopausal women with a past perimenopausal depression. To evaluate the efficacy and safety of a selective estrogen receptor (ER) beta agonist (Lilly Compound LY500307) to prevent estradiol withdrawal-induced mood symptoms. Eligibility: Healthy, non-depressed postmenopausal women, ages 45 to 65, with a well-documented past perimenopause-related depression (within 12 years) and whose mood systems got better with estradiol Design: Participants will be screened with: Medical history Physical exam Blood tests Psychiatric interview Gynecological exam * Participants able to get pregnant must use effective barrier birth control throughout the study. * During the first 3 weeks, participants will wear an estrogen patch. It is 1x2 inches and will be replaced every 3 days. * For the next 3 weeks, participants will take 3 study capsules every morning. They will not know if they get the study drug or placebo. * Some participants will also take a progesterone-like drug for 1 week at the end of the medication phase of the study. * Participants will have 9 one-hour study visits. They will have blood samples and vital signs taken. They will answer questions about mood and behavior symptoms. * Participants will keep a daily log of these symptoms. * Participants will have 2 transvaginal ultrasounds. A probe is temporarily placed 2-3 inches into the vaginal canal and sound waves are used to c

Primary Outcome

Center for Epidemiologic Studies-Depression (CES-D) Scale is a 20-item questionnaire that asks participants to rate how often over the past week they experienced symptoms associated with depression. Each item is rated from 0 to 3 (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Total scores range from 0 to 60, with high scores indicating greater depressive symptoms. CES-D scores \>8 and \<16 is consistent with

Interventions

  • OTHER Placebo
  • DRUG Estradiol
  • DRUG Provera
  • DRUG ER Beta Agonist

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2019-05-23
Est. Completion 2024-09-09
Phase Phase 2

What the finished NCT03689543 record still lists

NCT03689543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT03689543 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03689543 about?

NCT03689543 is a clinical study titled "Estrogen Receptor Beta and Mood". Background: Our previous studies have found that women who had depression during the perimenopause may have mood symptoms again if they stop estrogen therapy. Estrogen acts in the brain and other tissues by binding to estrogen receptors. There are two main types of estrogen receptors. They are estr...

What is the current status of trial NCT03689543?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2019-05-23. Estimated completion is 2024-09-09.

What interventions are being tested in trial NCT03689543?

The interventions under investigation include: Placebo (OTHER), Estradiol (DRUG), Provera (DRUG), ER Beta Agonist (DRUG).

Who is sponsoring clinical trial NCT03689543?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03689543's enrollment target sits among peer trials

74 920th of 2000 higher than 1,077 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03689543, the US trial registry maintained by the National Library of Medicine. NCT03689543 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.